Back to news

Ensysce Biosciences Announces Participation in Upcoming Investor Conferences

ACCESSWIRE•16/11/2026•16:15 ET
0

Key Highlights

  • ➤Ensysce management will participate in two upcoming investor conferences.
  • ➤UBS Healthcare Therapeutics fireside chat scheduled for November 17, 2026.
  • ➤Piper Sandler Healthcare presentation scheduled for December 3, 2026.
  • ➤Ensysce recently acquired Cy Biopharma, a clinical-stage chronic pain biotechnology company.

Expert Statements

James Morrison, Chief Executive Officer of Cy Biopharma

“management of the recently acquired Cy Biopharma Inc.”

Roger Sawhney, MD, Chief Financial Officer and Chief Business Officer of Cy Biopharma

“management of the recently acquired Cy Biopharma Inc.”

Prof. Richard Langford, Chief Medical Officer of Cy Biopharma

“management of the recently acquired Cy Biopharma Inc.”

SAN DIEGO, CA / ACCESS Newswire / November 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that management of the recently acquired Cy Biopharma Inc., James Morrison, Chief Executive Officer; Roger Sawhney, MD, Chief Financial Officer and Chief Business Officer; and Prof. Richard Langford, Chief Medical Officer, will participate in two upcoming investor conferences:

A live webcast of the UBS fireside chat can be accessed here.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in